4Raphael J, Ahmedzai S, HesterJ, et al. Cancer pain: part 1: Patho- physiology; oncological, pharmacological, and psychological treat- ments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners~. Pain Med, 2010, 11(5):742-764.
5Dalai S, Bruera E. Assessing cancer pain[J]. Curr Pain Headache Rep, 2012, 16(4):314-324.
7Dworkln RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an over- view and literature update . Mayo Clin Proc, 2010, 85(3 Suppl): $3-S14.
8Swarm RA, Abemethy AP, Anghelescu DL, et al. Adult cancer pain[J]. J Nail Compr Canc Netw, 2013, 11 (8):992-1022.
7Chang VT, Janjan N,Jain S, et al. Update in cancer pain syndromes[J]. J Palliat Med, 2006,9 (6) : 1414- 1434.
8Bickel Swenson D. End-of-life training in U. S. medical schools: a systematic literature review[J].J Palliat Med,2007,10(1) :229 -235.
9Lagman R, Rivera N, Walsh D, et al. Acute inpatient palliative medicine in a cancer center: clinical problems and medical interventions-a prospective study[J]. Am JHosp Palliat Care,2007,24(1) :20-28.
10Sloan PA. The evolving role of interventional pain management in oncology. J Support Oncol, 2004, 2:491 - 500, 503.
2Raphael J, Ahmedzai S, HesterJ, et al. Cancer pain: part 1: Patho- physiology; oncological, pharmacological, and psychological treat- ments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners[J]. Pain Med, 2010, 11 (5) :742-764.
5Edwards SR, Smith MT. Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-elec- trospray ionization-tandem mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 848(2):264-270.
6Nakamura A, Hasegawa M, Minami K, et al. Differential activa- tion of the mopioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model[J]. British Journal of Pharmacology, 2013, 168:375-388.
7Pan H, Zhang Z, Zhang Y, et al. Efficacy and tolerability of oxy- codone hydrochloride controlled-release tablets in moderate to severe cancer pain[J]. Clin Drug Investig, 2007, 27(4):259-267.
8Imanaka K, Tominaga Y, Etropolski M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean pa- tients with moderate to severe, chronic malignant tumor related pain[J]. Curr Med Res Opin, 2013, 29(10):1399-1409.
9Wang YM, Liu ZW, LinJL, et al. Efficacy and tolerability of oxy- codone hlmoderate-severe cancer related pain: A meta analysis of randomized controlled trials[J]. Exp Ther Med, 2012, 4(2):249- 254.
10Baek SK, Shin HW, Choi YJ, et al. Noninterventional observation- al study using high-dose controlled-release oxycodone (cr oxyco- done) for cancer pain management in outpatient clinics[J]. Pain Medicine, 2013, 14(12):1866-1872.
